key: cord-0773288-0kceuc2i authors: Blickstein, Dorit; Koren Michowitz, Maya title: Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Reply to comment from Doyle et al. date: 2022-02-26 journal: J Thromb Haemost DOI: 10.1111/jth.15634 sha: 67759a4cdacfc0c4df0ff20905b88dec183a919d doc_id: 773288 cord_uid: 0kceuc2i nan There are reports on aTTP association with other vaccines (e.g., H1N1 vaccine, pneumococcal vaccine) as mentioned in our report, 1 so that COVID-19 vaccine-aTTP association is not different from previously described vaccine-associated aTTP. Interestingly, the third BNT162b2 vaccine in Israel was associated with immune thrombocytopenic purpura (ITP) and not aTTP (data not reported yet), suggesting that there may be a dosedependent immune modulation. aTTP associated with BNT162b2 vaccine is rare; therefore, we strongly support the use of COVID-19 vaccines in the general population including aTTP patients. As discussed in our report, we suggest having protective measures before and after COVID-19 vaccination in aTTP patients. 1 We strongly agree with the authors for the need of reporting aTTP presentations following COVID-19 vaccination to a national reporting system scheme. The authors declare no competing financial interests. Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine Recurrence of thrombotic thrombocytopenic purpura after mRNA-1273 COVID-19 vaccine administered shortly after COVID-19 Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination